Yiren Digital Wins "Technology Innovation Leadership Award for Listed Companies" at the 23rd China's Financial Annual Champion Awards

Yiren Digital Wins "Technology Innovation Leadership Award for Listed Companies" at the 23rd China's Financial Annual Champion Awards

BEIJING, Dec. 11, 2025 /PRNewswire/ -- Yiren Digital Ltd. (NYSE: YRD) ("Yiren Digital" or the "Company"), a leading Fintech company specializing in digital consumer lending, insurance and financial technology innovation across China and Southeast...

Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025

Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented at ESMO IO 2025

HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the presentation of a Phase II clinical study that included a longer-term efficacy data evaluating ivonescimab (a PD-1/VEGF bispecific antibody)...

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment

-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter...

iQIYI Scream Night 2025 Spotlights Creative Excellence and Industry Momentum

iQIYI Scream Night 2025 Spotlights Creative Excellence and Industry Momentum

iQIYI and Galaxy Arena renew three-year strategic partnership to boost entertainment and tourism BEIJING, Dec. 10, 2025 /PRNewswire/ -- On December 6, iQIYI, China's leading online entertainment platform, hosted its annual Scream Night at the Galaxy...

Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody

Innovent Announces First Participant Dosed in a Phase 1 Clinical Trial of IBI3011, a Recombinant Anti-Human Interleukin 1 Receptor Accessory Protein Monoclonal Antibody

SAN FRANCISCO and SUZHOU, China, Dec. 10, 2025 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...

Nobel Sustainability Trust Successfully Concludes 2025 Miami Summit

Nobel Sustainability Trust Successfully Concludes 2025 Miami Summit

MIAMI, Dec. 10, 2025 /PRNewswire/ -- The Nobel Sustainability Trust (NST) successfully hosted its 2025 Annual Summit in Miami on 5 December 2025, at the St. Regis Bal Harbour Resort, bringing together global leaders, policymakers, scientists,...

HABANOS, S.A. PRESENTED PUNCH PRINCESAS: A NEW LIMITED EDITION CELEBRATING THE BRAND'S 185TH ANNIVERSARY

HABANOS, S.A. PRESENTED PUNCH PRINCESAS: A NEW LIMITED EDITION CELEBRATING THE BRAND'S 185TH ANNIVERSARY

Punch commemorates its 185-year history with the launch of Punch Princesas Edición Limitada 2025 , a new vitola that revives a popular format from the 1960s. This Limited Edition has been made '"Totally Handmade with Long Filler", aged for at least...

Fairchild Media Group and Hong Kong Fashion Council jointly celebrated WWD x SJ Global Fashion & Business Conference and WWD Fashion Loves Culture Gala in Hong Kong

Fairchild Media Group and Hong Kong Fashion Council jointly celebrated WWD x SJ Global Fashion & Business Conference and WWD Fashion Loves Culture Gala in Hong Kong

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Leading fashion media outlets Women's Wear Daily (WWD) and Sourcing Journal (SJ) co-presented the WWD x SJ Global Fashion & Business Conference and WWD Fashion Loves Culture Gala, in partnership with the...

Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025

Phase II Data of Cadonilimab Regimen as Neoadjuvant Therapy for Resectable Gastric Cancer Presented at ESMO Asia 2025

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that data from the Phase II study (COMPASSION-25) for its first-in-class PD-1/CTLA-4 bispecific antibody, cadonilimab, in combination with SOX regimen...

Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia

Significant Improvement in Quality of Life Reported in Updated HARMONi-6 Data for Ivonescimab at ESMO Asia

HONG KONG, Dec. 9, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that at the 2025 ESMO Asia Congress, updated results from the pivotal Phase III HARMONi-6 study (AK112-306) were shared in an oral presentation by...

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...
  • 21
  • menu
    menu